Auayporn Nademanee
Overview
Explore the profile of Auayporn Nademanee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
2951
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mei M, Palmer J, Tsai N, Simpson J, OHearn J, Stein A, et al.
Clin Lymphoma Myeloma Leuk
. 2023 Jun;
23(9):e268-e276.
PMID: 37301631
Background: Allogeneic hematopoietic stem cell transplantation (alloHCT) is potentially curative for relapsed/refractory (r/r) B-cell non-Hodgkin's lymphoma (B-cell NHL). However, relapse remains a major cause of treatment failure, especially in patients...
2.
Herrera A, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, et al.
Lancet Haematol
. 2022 Nov;
10(1):e14-e23.
PMID: 36403579
Background: After autologous haematopoietic stem-cell transplantation (HSCT), consolidation with brentuximab vedotin in patients with high-risk relapsed or refractory classic Hodgkin lymphoma has been shown to improve progression-free survival compared with...
3.
Mei M, Lee H, Palmer J, Chen R, Tsai N, Chen L, et al.
Blood
. 2022 Mar;
139(25):3605-3616.
PMID: 35316328
This phase 2 trial evaluated PET-adapted nivolumab alone or in combination with ifosfamide, carboplatin, and etoposide (NICE) as first salvage therapy and bridge to autologous hematopoietic cell transplantation (AHCT) in...
4.
Herrera A, Palmer J, Adhikarla V, Yamauchi D, Poku E, Bading J, et al.
Blood Adv
. 2021 Oct;
5(23):5300-5311.
PMID: 34638132
High-risk relapsed or refractory (R/R) classical Hodgkin lymphoma (HL) is associated with poor outcomes after conventional salvage therapy and autologous hematopoietic cell transplantation (AHCT). Post-AHCT consolidation with brentuximab vedotin (BV)...
5.
Ciurea S, Al Malki M, Kongtim P, Zou J, Aung F, Rondon G, et al.
Blood Adv
. 2021 Sep;
5(20):4031-4043.
PMID: 34474478
Donor-specific anti-HLA antibodies (DSAs) are a major cause of engraftment failure in patients receiving haploidentical stem cell transplantation (HaploSCT). Effective treatments are needed for these patients, who often have no...
6.
Nikolaenko L, Nademanee A
Future Oncol
. 2020 Jul;
16(29):2273-2282.
PMID: 32677451
Brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, is US FDA approved for treatment of classic Hodgkin lymphoma (cHL) after progression or relapse of at least two prior lines of chemotherapy...
7.
Al Malki M, Song J, Yang D, Cao T, Aldoss I, Mokhtari S, et al.
Biol Blood Marrow Transplant
. 2020 Jun;
26(9):1697-1703.
PMID: 32534103
The negative impact of iron overload (IO) on outcomes of allogeneic hematopoietic cell transplantation (HCT) is well recognized, but its impact on umbilical cord blood (UCB) transplant outcome is unknown....
8.
Aldoss I, La Rosa C, Baden L, Longmate J, Ariza-Heredia E, Rida W, et al.
Ann Intern Med
. 2020 Feb;
172(5):306-316.
PMID: 32040960
Background: Triplex vaccine was developed to enhance cytomegalovirus (CMV)-specific T cells and prevent CMV reactivation early after hematopoietic stem cell transplant (HCT). Objective: To determine the safety and efficacy of...
9.
Al Malki M, Gendzekhadze K, Stiller T, Mokhtari S, Karanes C, Parker P, et al.
Bone Marrow Transplant
. 2019 Sep;
55(2):409-418.
PMID: 31551519
A mismatch at HLA-DPB1 locus is associated with higher acute GVHD and lower relapse rate after myeloablative (MAC) allogeneic hematopoietic cell transplantation (alloHCT). Also, in MAC setting, mismatch permissiveness and...
10.
Al Malki M, Gendzekhadze K, Yang D, Mokhtari S, Parker P, Karanes C, et al.
Transplantation
. 2019 Aug;
104(5):1070-1080.
PMID: 31449184
Background: While tacrolimus and sirolimus (T/S)-based graft-versus-host disease (GvHD) prophylaxis has been effective in preventing acute GvHD post hematopoietic cell transplantation (HCT), its efficacy and long-term outcome in matched (MUD)...